BioNTech SE (NASDAQ:BNTX) Short Interest Up 22.3% in November

BioNTech SE (NASDAQ:BNTX - Get Free Report) saw a large growth in short interest in the month of November. As of November 15th, there was short interest totalling 2,470,000 shares, a growth of 22.3% from the October 31st total of 2,020,000 shares. Based on an average trading volume of 1,120,000 shares, the short-interest ratio is presently 2.2 days.

Wall Street Analysts Forecast Growth

BNTX has been the topic of a number of recent research reports. Jefferies Financial Group raised BioNTech from a "hold" rating to a "buy" rating and lifted their price objective for the company from $96.00 to $150.00 in a report on Tuesday, September 17th. Canaccord Genuity Group upped their price target on BioNTech from $171.00 to $171.44 and gave the company a "buy" rating in a research report on Wednesday. Evercore ISI upgraded BioNTech from an "in-line" rating to an "outperform" rating and increased their price objective for the stock from $110.00 to $125.00 in a research note on Tuesday, November 19th. TD Cowen reduced their target price on shares of BioNTech from $132.00 to $122.00 and set a "hold" rating on the stock in a research note on Tuesday, November 5th. Finally, Bank of America increased their target price on shares of BioNTech from $125.00 to $150.00 and gave the stock a "buy" rating in a research report on Monday, September 16th. Four equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $138.67.

BioNTech Stock Performance

The firm has a market cap of $28.38 billion, a P/E ratio of -56.38 and a beta of 0.26. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The stock's 50-day moving average price is $113.81 and its two-hundred day moving average price is $98.73. BioNTech has a 1-year low of $76.53 and a 1-year high of $131.49.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.26) by $2.07. The business had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm's revenue for the quarter was up 38.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.73 earnings per share. On average, equities analysts predict that BioNTech will post -3.72 EPS for the current fiscal year.

Institutional Investors Weigh In On BioNTech

Institutional investors and hedge funds have recently modified their holdings of the business. Baillie Gifford & Co. boosted its stake in BioNTech by 0.4% in the third quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company's stock valued at $986,750,000 after acquiring an additional 31,773 shares during the last quarter. FMR LLC boosted its position in shares of BioNTech by 797.8% in the 3rd quarter. FMR LLC now owns 6,299,929 shares of the company's stock worth $748,243,000 after purchasing an additional 5,598,190 shares during the last quarter. Deerfield Management Company L.P. Series C grew its stake in shares of BioNTech by 4.3% during the second quarter. Deerfield Management Company L.P. Series C now owns 594,000 shares of the company's stock worth $47,734,000 after purchasing an additional 24,426 shares during the period. Candriam S.C.A. increased its holdings in BioNTech by 261.2% in the second quarter. Candriam S.C.A. now owns 578,998 shares of the company's stock valued at $46,526,000 after purchasing an additional 418,695 shares during the last quarter. Finally, Fred Alger Management LLC bought a new stake in BioNTech in the third quarter valued at about $59,485,000. 15.52% of the stock is owned by institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.